Macleods Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MACLEODS PHARMS
MACLEODS PHARMS has one hundred and sixty approved drugs.
There are thirteen tentative approvals on MACLEODS PHARMS drugs.
Summary for Macleods Pharms
| US Patents: | 0 |
| Tradenames: | 132 |
| Ingredients: | 131 |
| NDAs: | 160 |
Drugs and US Patents for Macleods Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Macleods Pharms | CANDESARTAN CILEXETIL | candesartan cilexetil | TABLET;ORAL | 203813-004 | Dec 5, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Macleods Pharms | PREGABALIN | pregabalin | CAPSULE;ORAL | 205924-004 | Nov 12, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Macleods Pharms | ZONISAMIDE | zonisamide | CAPSULE;ORAL | 219507-003 | May 12, 2025 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for MACLEODS PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
